Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. (Nasdaq: MDVN) announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal…
Source:EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer
Monday, June 24, 2013
EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment